Episode

GLP-1s for Employers: Navigating What’s Next

Podcast
The Granite List Live
Published
Jan 26, 2026
Duration seconds
1000
Processing state
not_requested
Canonical source
https://thegranitelist.live/e/glp-1s-for-employers-navigating-what-s-next/
Audio
https://mcdn.podbean.com/mf/web/5ghewpd7ddv8jece/tgl-tria_26.mp3
JSON
/v1/public/podcasts/the-granite-list-live-6598764/episodes/glp-1s-for-employers-navigating-what-s-next
Markdown
/podcast/the-granite-list-live-6598764/glp-1s-for-employers-navigating-what-s-next.md

Actions

  • POST https://stenobird.com/v1/public/podcasts/the-granite-list-live-6598764/episodes/glp-1s-for-employers-navigating-what-s-next/transcription-requests
    Idempotently request low-priority transcript generation for this episode.
  • GET https://stenobird.com/podcast/the-granite-list-live-6598764/glp-1s-for-employers-navigating-what-s-next.md
    Read the agent-friendly Markdown representation of this episode resource.

Summary

This week on The Granite List.Live, Sally is joined by Jessica Lea, PharmD and CEO of Tria Health, as they dive into the fast-changing landscape of GLP-1 medications for obesity and diabetes. Jessica shares her insight on why pharmacist-led oversight is important, especially with complex and costly drugs like Ozempic and Wegovy. Additionally, together, Sally and Jessica explore: Challenges employers face when deciding whether to cover these medications The impact of direct-to-consumer options The importance of combining medication with lifestyle changes for lasting results Future developments in GLP-1 treatments and their potential uses. Learn more about Tria Health on The Granite List!